Implanet received FDA 510(k) clearance to market its Squale anterior cervical cage.
Squale features a range of implants, a design adapted to vertebral anatomy and radiolucency for optimal radiographic confirmation of interbody fusion. To date, more than 15,000 Squale cages have been implanted worldwide.
Squale is part of the portfolio acquired by Implanet in 2021 with the purchase of a majority stake in Orthopaedic & Spine Development.
Ludovic Lastennet, Implanet’s Chief Executive Officer, said, “The Implanet America sales teams should be able to launch the marketing of this anterior cervical cage range before the summer of 2023.”
Implanet received FDA 510(k) clearance to market its Squale anterior cervical cage.
Squale features a range of implants, a design adapted to vertebral anatomy and radiolucency for optimal radiographic confirmation of interbody fusion. To date, more than 15,000 Squale cages have been implanted worldwide.
Squale is part of the portfolio...
Implanet received FDA 510(k) clearance to market its Squale anterior cervical cage.
Squale features a range of implants, a design adapted to vertebral anatomy and radiolucency for optimal radiographic confirmation of interbody fusion. To date, more than 15,000 Squale cages have been implanted worldwide.
Squale is part of the portfolio acquired by Implanet in 2021 with the purchase of a majority stake in Orthopaedic & Spine Development.
Ludovic Lastennet, Implanet’s Chief Executive Officer, said, “The Implanet America sales teams should be able to launch the marketing of this anterior cervical cage range before the summer of 2023.”
Copy to clipboard 
